A Case Report for Myopericarditis after BNT162b2 COVID-19 mRNA Vaccination in a Korean Young Male
10.3346/jkms.2021.36.e277
- Author:
Dongwon KIM
1
;
Jun Hyung CHOI
;
Jun Young JANG
;
Ouiyeon SO
;
EunJeong CHO
;
Hyunhee CHOI
;
Kyung Soon HONG
;
Kyu Tae PARK
Author Information
1. Division of Cardiology, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea
- Publication Type:Case Report
- From:Journal of Korean Medical Science
2021;36(39):e277-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Mass vaccination with the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine (BNT162b2) in Korea has resulted in many reported adverse effects. These side effects are the object of much scrutiny in the medical community. We report the case of a 29-year-old male who was diagnosed with myopericarditis after his second dose of Pfizer-BioNTech COVID-19 vaccine. This patient is the second recognized case of Pfizer-BioNTech COVID-19 vaccine induced myopericarditis in Korea and the first to have recovered from it. He originally presented with chest discomfort and exertional chest pain. Lab tests revealed elevated cardiac marker levels and echocardiographic findings displayed minimal pericardial effusion, prompting diagnosis as myopericarditis. We decided on two weeks of outpatient treatment with non-steroidal anti-inflammatory drugs (NSAIDs) due to the patient's mild symptoms and his occupation in the military. When this proved insufficient, we shifted to combination therapy with low dose corticosteroids and NSAIDs. After two weeks of treatment, the patient's symptoms and pericardial effusion had improved, and he was recovered completely 37 days after the onset.
